Q-omics provides the consensus-scored MPO profile across patient tissues and cancer cell-line models. MPO expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MPO is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, MPO protein abundance shows 33,843 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, COAD, and GBM as cancer lineages where MPO shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MPO — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MPO survival associations across molecular data types. MPO RNA expression shows survival associations in the most cancer types (29), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MPO RNA expression–survival associations across cancer types. High MPO expression shows unfavorable associations in STAD and COAD, but favorable associations in KICH, LAML, KIRP and UCS. The KICH Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify KICH as the clearest survival context for MPO RNA expression.
This table summarizes MPO tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MPO. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MPO shows lower tumor expression in LUSC, HNSC, BRCA and KICH and higher tumor expression in COAD and KIRP. The COAD box plot shows higher MPO RNA expression in tumor versus normal tissue (log2 FC = +0.514, t-test p = .001).
This table shows molecular features associated with MPO in patient tissues and cancer cell lines. In patient samples, MPO shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MPO RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
